Found: 6
Select item for more details and to access through your institution.
PARP inhibitors in metastatic prostate cancer.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1159557
- By:
- Publication type:
- Article
The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG‐ACRIN Cancer Research Group trials.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 3, p. 439, doi. 10.1002/cncr.35039
- By:
- Publication type:
- Article
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).
- Published in:
- 2021
- By:
- Publication type:
- journal article
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 2, p. 179, doi. 10.1007/s10637-024-01419-1
- By:
- Publication type:
- Article
Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison.
- Published in:
- Clinical Medicine Insights: Oncology, 2014, n. 8, p. 29, doi. 10.4137/CMO.S13671
- By:
- Publication type:
- Article
Neutropenic Fever–Associated Admissions Among Patients With Solid Tumors Receiving Chemotherapy During the COVID-19 Pandemic.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 3, p. e234881, doi. 10.1001/jamanetworkopen.2023.4881
- By:
- Publication type:
- Article